Drugs / Anti-Thymoglobulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04118075 | Jan 2019 → May 2021 | acute graft versus host disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06252870 Background | Jul 2024 → Oct 2027 expected | graft versus host disease, hematopoietic and lymphoid cell neoplasm | Nantes University Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-Thymoglobulin | “we evaluated the effect of a new GVHD prophylaxis consist of PT-Cy combined with tacrolimus and low dose anti-thymoglobulin (ATG).” PMID 33816524 ↗ Mar 2021 |
| Known as | ATG | “we evaluated the effect of a new GVHD prophylaxis consist of PT-Cy combined with tacrolimus and low dose anti-thymoglobulin (ATG).” PMID 33816524 ↗ Mar 2021 |